Background: Recurrent abdominal pain is a common and costly health-care problem attributed, in part, to visceral hypersensitivity. Increasing evidence suggests that gut bacteria contribute to abdominal pain perception by modulating the microbiome-gutbrain axis. However, specific microbial signals remain poorly defined. γ-aminobutyric acid (GABA) is a principal inhibitory neurotransmitter and a key regulator of abdominal and central pain perception from peripheral afferent neurons. Although gut bacteria are reported to produce GABA, it is not known whether the microbial-derived neurotransmitter modulates abdominal pain.
with disturbances of the intestinal microbiome, and may precede CNS symptoms. 7, 8 Whether gut microbes play a role in such disease etiologies is not clearly established, although recent reports in animal models implicate microbiome-gut-brain signaling.
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Functional GI disorders, for example, irritable bowel syndrome (IBS) and constipation, represent a spectrum of diseases with active bidirectional gut-brain communication. 9 A subset of patients with IBS (30-40%) have been reported to experience enhanced sensitivity to colonic distension, accompanied by a reduced threshold for pain and increased intensity of sensation. 16 Visceral hypersensitivity has therefore been used as a clinical marker in this subset of patients with IBS.
The cause of visceral hypersensitivity is unknown; however, the recurrent abdominal pain that is attributed, in part, to visceral hypersensitivity is a common and costly health-care problem. Metagenomic studies revealed that the human microbiome has the potential to generate numerous bioactive molecules, including but not limited to histamine, epinephrine, and γ-aminobutyric acid (GABA). 3, 4, 24, 25 Although Lactobacillus 26 and Bifidobacterium 27, 28 species are reported as GABA-producing bacteria, the links between microbial production and neuromodulatory activity in vivo have not been established. γ-aminobutyric acid is a primary inhibitory CNS neurotransmitter in mammals, 29 exerting its major functional effects via two GABA receptor subclasses-GABA A and GABA B . 30 However, GABA bioactivity is evolutionally conserved throughout the animal kingdom. In mammals, GABA has diverse physiologic effects, such as modulation of blood pressure 31 and immune function, 32 and it is also known to promote stress tolerance and ATP production in microbial communities. [33] [34] [35] [36] A major source of bioactive GABA is the enzymatic conversion of l-glutamate by glutamate decarboxylase by both microbes and host. 37, 38 The potential health benefits of GABA have fueled a growing interest in GABA-enriched dietary supplements and naturally fermented food products. 27 We hypothesized that in vivo production of GABA by commensal bacterial species would modulate the excitability of colonic sensory afferents. We aimed to demonstrate the neuromodulatory properties of microbial-derived GABA in an animal model of constipation and visceral pain and to show that GABAergic signaling via the microbiome-gut-brain axis is mechanistically linked to glutamate decarboxylation by the common human commensal bacterium, Bifidobacterium dentium.
| METHODS

| Bacterial strains, cell lines, media, and culture conditions
Bacterial strains and plasmids used in this study are listed in Table 1 . 
| In silico analysis of human microbiome and metagenomic data
To determine the distribution and relative abundances (RAs) of the glutamate decarboxylase-encoding gad genes at various sites across the human body, Human Microbiome Project (HMP) 24 metabolic reconstruction profiles, as generated by the HUMAnN software package, 40 were obtained from the HMP Data Analysis and Coordination Center (http://www.hmpdacc.org/HMMRC/). From these profiles, the RA of the KEGG ortholog for gadB (K01580), across subjects and body sites, was obtained.
To identify potential genomes within the stool microbiome containing glutamate decarboxylases, the Integrated Microbial Genomes
Key Points
• Recurrent abdominal pain is a common and costly health-care problem attributed, in part, to visceral hypersensitivity.
• Intestinal bacteria capable of producing the primary inhibitory CNS neurotransmitter, γ-aminobutyric acid (GABA), modulate primary sensory neurons of the enteric nervous system.
The production of GABA by the intestinal microbiome can be increased by supplementing bacteria encoding the glutamate decarboxylase gene gadB.
• GABA produced by the intestinal microbiome may form the basis of future nutritional interventions or microbiome-based therapeutics that ameliorate abdominal pain.
(IMG)/HMP database (http://img.jgi.doe.gov) 41 was used to search 
| Screening for bacterial GABA production
Nine Lactobacillus sp., five Bifidobacterium sp., and four Alistipes sp.
strains were screened for their ability to consume l-glutamate and secrete GABA (Table 1) . Lactobacilli and Bifidobacterium sp. strains were cultured in MRS or mMRS, while Alistipes sp. strains were cultured in MTGE and mMTGE. Growth medium was inoculated with 1% inoculum of overnight cultures (12 hours), followed by incubation anaerobically at 37°C for 48 hours. Cells were removed by centrifugation and cell-free supernatants were subjected to filtration through 3 kDa MWCO filters (Amicon, Bedford, MA, USA), following LC-MS analysis (Data S1) for the detection of secreted GABA and l-glutamate. 
| In silico analysis of GadB structure
| Enzyme assay and determination of glutamate decarboxylase activity by rGadB
In vitro enzymatic reactions with rGadB and its derivatives were performed as previously described by Hiraga et al. 
Su et al. for 20 minutes. The mixture was then heat inactivated by boiling for 5 minutes to stop the decarboxylation reaction. Reaction mixtures were subsequently analyzed for the presence of GABA and glutamate using LC-MS analysis (details of LC-MS analysis are provided in Data S1).
| Construction of recombinant B. breve NCIMB8807
Construction of B. dentium ATCC 27678 gadB plasmid was performed as follows. B. dentium ATCC 27678 genomic DNA served as a template to amplify gadB by PCR using gadB-specific oligonucleotide primers (Table S1 ). The gadB PCR product was amplified with Takara The recombinant B. breve NCIMB8807 harboring pESHgadB plasmid was screened for its ability to secrete GABA as follows. The recombinant strain, wild-type B. breve NCIMB8807 (negative control), and B. dentium ATCC 27678 (positive control) were grown in MRS medium supplemented with 0.05% (w/v) l-cysteine-HCl for 48 hours, and the cell free supernatants were analyzed using LC-MS analysis (Data S1).
| In vivo GABA measurement
| Animals
Six-week-old, male, Swiss Webster mice (n=6-8 per group, 30 total)
were purchased from Taconic Biosciences and were maintained under specific-pathogen-free (SPF) conditions. Mice were kept under filtertop cages (3-4 mice per cage) and had free access to distilled water and LabDiet 5V5R rodent chow, containing 5.09% glutamate. All mouse experiments were performed in the SPF animal facility according to an Institutional Animal Care and Use Committee-approved mouse protocol at Baylor College of Medicine, Houston, TX.
| Bifidobacterial strain administration
Bifidobacterium strains (B. dentium ATCC 27678, B. breve NCIMB 8807, and B. breve NCIMB8807 pESHgadB) were grown in culture conditions described above. Bacteria were harvested in early-stationary phase (12 hours growth in mMRS medium or mMRS supplemented with 5 μg/mL Erm to maintain the plasmid in B. breve pESHgadB).
OD600 of the culture was used to approximate cell viability based on previous growth curve data (Fig. S1 ). The culture volume required for approximately 8 × 10 8 CFU/mL was centrifuged at 5,000 x g for 5 minutes to pellet the bacterial cells. The cells were then washed in pre-reduced PBS (PBS + 0.05% l-cysteine) and re-pelleted. The wash was performed to minimize the amount of GABA administered to the T A B L E 2 Oligonucleotide primers used in this study
Primer name
Sequence code (5′→3′)
The underlined sequence corresponds to an NcoI site. b The underlined sequence corresponds to an HindIII site. c The underlined sequence corresponds to the introduced mutation site for
Threonine. d The underlined sequence corresponds to the introduced mutation site for
Aspartate. e The underlined sequence corresponds to the introduced mutation site for
Lysine. f The underlined sequence corresponds to the introduced mutation site for
Threonine. The underlined sequence corresponds to the introduced mutation site for Aspartate.
h
The underlined sequence corresponds to the introduced mutation site for Lysine.
i
The underlined sequence corresponds to an XhoI site. The underlined sequence corresponds to an BamHI site. k B. breve NCIMB8807 strain-specific primers have been described previously by Pokusaeva et al.
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mice 
| Fecal water preparation
Samples of cecal content (50-80 mg) were manually homogenized in 1 mL of DEPC-treated water by vigorous vortexing until slurry was produced. The mixture was centrifuged at 5000 g for 5 minutes.
The supernatant (fecal water) was carefully decanted into 1.5 mL
Eppendorf tubes and stored frozen (−20°C) until analysis; 100 μL of this preparation was used in subsequent GABA ELISA.
| GABA measurement via ELISA
γ-aminobutyric acid concentrations in cecum content were measured via GABA ELISA (LDN Immunoassays, Nordhorn, Germany)
according to manufacturer instructions. Briefly, after extraction and derivatization, GABA was quantitatively determined by competitive ELISA using an anti-rabbit IgG-peroxidase conjugate with 3,3′,5,5′-tetramethylbenzidine as a substrate. All samples and standards were run in duplicate, and the reaction was monitored at 450 nm.
The resulting ng/mL values were background adjusted using 650 nm as a reference wavelength, and results were normalized to initial weight of sample.
| Rat fecal retention model
| Animals
Male Sprague-Dawley rats (n=4 per group) of 225-250 g were used for this study. The Institutional Animal Care and Use Committee of the University of Texas Medical Branch at Galveston, TX, approved the study using Sprague-Dawley rats. Rats were anesthetized with 2% isoflurane with an E-Z Anesthesia System. A 20-mm-circumference glass rod was inserted into the rat anus. A purse-string suture was placed in the external sphincter to keep the lumen of the anus around the rod, and then the rod was removed.
The outlet occlusion was kept for 3 days. This treatment significantly reduced fecal output and led to lumen distention in the distal colon, which significantly increased colon-specific sensory neuron excitability. Age-matched control rats were treated similarly, except that the suture was removed immediately after being placed. B. dentium 
| Retrograde fluorescence label injections
Labeling of colon-specific dorsal root ganglia (DRG) neurons was performed as previously described. 51 Under general 2% isoflurane anesthesia, the lipid soluble fluorescence dye, 1,1′-dioleyl-3,3,3′,3′-tetra methylindocarbocyanine methanesulfonate (DiI, Invitrogen) (50 mg/ mL), was injected into muscularis externae of the distal colon in 8-10 sites (2 μL each site). To prevent leakage, the needle was kept in place for 1 minute following each injection.
| Dissociation of DRG neurons
Control and FR rats were euthanized by cervical dislocation, followed 
| Whole-cell patch clamp recordings from dissociated DRG neurons
Before each experiment, the glass coverslip with DRG neurons was transferred to recording chamber perfused (1. 
| RESULTS
| Microbial glutamate decarboxylase (gadB) is enriched in human intestine
GadB is the primary bacterial enzyme responsible for generating bioactive, microbe-derived GABA. The availability of metagenomic data from the HMP allowed us to determine the relative abundance (RA)
of gadB in the microbial genomes found at different body sites in 96 healthy adult individuals. Our analysis demonstrates that although bacterial gadB is present at multiple body sites, it is most abundant in adult human stool specimens (Fig. 1A) . Our results indicate that the gadB gene signature is present at nearly three-fold greater percentage in the stool microbiome vs the microbiomes at other body sites.
This result is not surprising, as the glutamate decarboxylase system is known for its role in acid-resistance, and contributes to bacterial survival during transit through the GI tract.
The RA of gadB in stool prompted us to investigate which microbes harbor glutamate decarboxylases (Fig. 1B) . 9.9%). Interestingly, the commensal bacteria B. dentium, which contains a gadB gene, was found to be present at a RA of 0.7% (Fig. 1B) .
Thus, microbial GadB is a potentially rich enzymatic source of bioactive GABA in the gut lumen, and this species represents a model organism for GABA-producing microbes.
| GadB-derived GABA secretion by B. dentium
In order to quantify GABA production by specific intestinal bacterial strains, 16 different commensal microorganisms were screened for GABA production capacity by LC-MS. Based on the Fig. 2A) .
From this microbial screening library, only four strains actively secreted increased quantities of GABA into MRS medium supplemented with glutamate ( Fig. 2A) , including L. plantarum NCIMB8826, L. plantarum ATCC14917, B. angulatum ATCC27535, and B. dentium ATCC 27678. This B. dentium strain was the only significant GABA secretor (P<0.0001) with the greatest amount of GABA produced among this group, and more than 1 mg/mL of GABA detected in vitro. Our efforts, therefore, focused on characterizing the mechanisms of GABA production in this human-derived commensal strain.
Taxonomic profiling of metagenomic sequencing data suggests that B. dentium may account for up to 0.18% (median value across all subjects evaluated) of the healthy human gut microbiome (Fig. 2B) .
The observed enrichment in pediatric samples (P=2.71e −6 ) may be partially explained by the increased overall abundance of Bifidobacterium species typically detected in children relative to adult samples. 42 To characterize the dynamics of GABA production by B. dentium ATCC 27678, its growth in MRS medium, glutamate consumption, and GABA F I G U R E 2 GABA production by commensal intestinal strains and Bifidobacterium dentium in the human gut microbiome. (A) Screening of 16 different intestinal commensal and/or probiotic isolates identified B. dentium ATCC 27678 as a major GABA producer. GABA concentrations were measured using LC-MS after 48 hours of anaerobic growth at 37°C in either regular MRS (dark green) or MRS medium supplemented with 1% w/v glutamate (light green). Error bars represent standard error of 3 independently performed experiments. B. dentium was the only species that produced significantly more GABA (P<.0001; two-way ANOVA with Bonferroni correction for multiple comparisons). (B) B. dentium in the healthy human gut microbiome, as detected by Metaphlan profiling of shotgun metagenomic sequence libraries. Different colors represent subject cohorts, while bars show proportion of sequences with hits to B. dentium found in each individual. The horizontal bars represent the average relative abundance (as determined by the proportion of sequences with hits to B. dentium) in each cohort secretion were monitored over 72 hours (Fig. S1 ). Unlike B. bifidum MIMBb13CS, which lacks the gadB gene, B. dentium secreted GABA by consuming glutamate in a stationary phase environment associated with low pH. These results confirmed and extended prior reports that B. dentium is a human-associated GABA-producing microbe. 27, 28 To confirm that GadB is the enzyme responsible for GABA production in B. dentium, we generated recombinant His-tagged wild-type and mutant GadB proteins to characterize the catalytic mechanism of glutamate decarboxylation. Homology modeling of GadB in B. dentium identified three conserved active site amino acids
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: lysine (K289), threonine (T225), and aspartic acid (D256) (Fig. 3A) . Each of these amino acids was separately mutated to alanine, and relative enzyme activities were measured in the presence of glutamate and PLP cofactor (Fig. 3B ). Using this quantitative approach, wild-type
GadB converted approximately 80% of the substrate, glutamate, into GABA, whereas mutant proteins were deficient in enzymatic activity.
Furthermore, to test whether GadB is sufficient for GABA production by bifidobacteria, gadB was cloned into the Bifidobacterium-E. coli shuttle vector pESH46, 47 transformed into B. breve NCIMB8807, and analyzed for GABA production. Since it is currently not possible to genetically delete gadB in B. dentium, we chose this highly transformable B. breve strain because it lacks gadB and does not produce
In vitro and in vivo activity of glutamate decarboxylase (GadB) from Bifidobacterium dentium. (A) GadB 3D structure with its proposed active site highlighted. Dark blue color depicts catalytic lysine at position 289 (K289), while threonine (T225) and aspartate (D256) are colored in light blue and red, respectively. Position of co-factor pyridoxal phosphate, PLP, is shown in green. (B) Site directed mutagenesis effect on recombinant GadB activity. pQE60-negative control of crude extract from Escherichia coli strain harboring empty pQE60 vector. GadB-WT-crude extract with recombinant wild-type GadB overexpressed in E. coli. GadB-T, GadB-D, and GadB-K are crude extracts of recombinant GadB with mutated amino acids from T225, D256, and K289 to alanine, respectively. Bars demonstrate GABA (dark green) or l-glutamate (light green) concentration. Error bars represent standard error of 3 independently performed experiments (*P<.01, **P<.05; one-way ANOVA of log transformed data, Bonferroni correction for multiple comparisons). (C) Expression of GadB from B. dentium in B. breve by complementation. gadB from B. dentium ATCC 27678 (BD) was cloned into the pESH46 (pESHgadB) expression vector and transformed into B. breve NCIMB8807 (BB) allowing for constitutive expression (BBgadB). GABA was measured via LC-MS method (Data S1). Error bars represent standard error of 3 independently performed experiments (****P<.0001, ns=not significant; one-way ANOVA of log transformed data, Bonferroni correction for multiple comparisons). (D) Six-week-old male Swiss Webster mice (n=6-8 per group) were orally administered 1% glutamate plus B. dentium ATCC 27678 (BD), B. breve NCIMB8807 (BB), B. breve NCIMB8807 pESHgadB (BBgadB), or saline (PBS) for 5 days. Mice administered B. breve pESHgadB had significantly more GABA in their cecal content as measured by ELISA (**P<.01; one-way ANOVA with Bonferroni correction)
GABA. 53 Constitutively expressed recombinant GadB in B. breve harboring pESHgadB produced GABA in comparable amounts to B. dentium in vitro (Fig. 3C) , demonstrating that GadB functions as a glutamate decarboxylase in B. dentium with conserved catalytic amino acid residues involved in PLP cofactor binding and glutamate decarboxylase activity.
| Microbial GABA production in vivo is mediated by GadB
To confirm that GadB-mediated GABA production occurs in an in vivo setting as well as in vitro, we used a murine model to examine how host GABA concentrations are affected by short-term colonization with these Bifidobacterium strains (Fig. 3D) . Six-week-old male Swiss Webster mice (n=6-8 per group) were orally administered 1% glutamate plus B. dentium, B. breve, B. breve pESHgadB, or saline (PBS) for 5 days. This oral gavage mimicked the natural route of gut microbial colonization. Inter-subject variation was observed in each group; however, mice administered B. breve pESHgadB had significantly more GABA in their cecal content than mice that received nonmodified B. breve (P<0.01; 18.4 ± 3.4 vs 7.8 ± 1.4 μg/g cecal content).
A trend toward increased GABA production was also observed in the mice that received B. dentium relative to those that received B. breve (10.1 ± 2.5 vs 7.8 ± 1.4 μg/g cecal content); however, GABA concentrations in the PBS-treated mice were also within a similar range (10.3 ± 1.7 μg/g cecal content).
Increased GABA production in cecal content of B. dentium colonized mice has also been demonstrated in previous pilot studies using mice pretreated with antibiotics (Fig. S2) . A trend toward increased GABA production was observed in mice receiving gadB-positive B. dentium compared with the gadB-negative B. breve (P>0.05; 14.2 ± 2.5 vs 5.4 ± 0.9 μg/g cecal content; n=6 per group). The increased GABA accumulation was not due to altered survival or transit of the bacteria since similar bacterial counts were measured in extracted cecal content (P>0.05; 1.7 × 10 7 and 6.7 × 10 7 copies of B. dentium and B. breve, respectively; n=6 per group) (Fig. S2) . Taken altogether, these data demonstrate that the gadB gene from B. dentium ATCC 27678 is sufficient to facilitate GABA production in vivo when cloned into other bacterial species, and that expression of the microbial gadB gene in vivo can result in significant increases in host intestinal GABA concentrations.
| B. dentium ATCC 27678 desensitizes sensory neuron activity in a rat model of visceral hypersensitivity
To determine if GABA-producing bifidobacterial strains have beneficial effects on abdominal pain in FR-associated constipation, we induced FR in rats by partial occlusion of the external anal sphincter as previously described. Furthermore, similar numbers of both Bifidobacterium strains were detected in stool specimens from treatment and control animals ( Fig. S3 ) and demonstrated a corresponding trend toward increased GABA in B. dentium-treated animals only. These data indicate that colonic-specific sensory neurons are hypersensitized following luminal distention associated with FR, and this hyperexcitability phenotype is inhibited by GABA-producing, gadB-positive B. dentium and not by a genetically similar non-GABA producer.
| DISCUSSION
We have shown that visceral hypersensitivity may be modulated by select GABA-producing members of the gut microbiota, implicating neurotransmitter production by the microbiota as a means of microbiome-gut-brain communication. Many amino acids can be metabolized by microbes to form biologically active amine compounds via decarboxylation. These reactions consume intracellular protons, resulting in increased pH within bacterial cells. In this way, the decarboxylation of amino acids (including glutamate) plays a central role in acid stress resistance among enteric 58 and lactic acid bacteria.
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Protection against the acidity of the mammalian stomach and acidic microenvironments within the intestinal lumen helps these bacteria survive and even colonize their host.
Amino acid decarboxylation can also generate strong proton motive forces in bacterial cells, which can increase ATP production, and metabolic activity by these cells. Glutamate decarboxylase (GAD or GadB, EC 4.1. ; however, this is the first in-depth study that investigates GABA secretion and its possible effect on the host. B. dentium is a representative taxon of the healthy human gut microbiome, 24 and strain ATCC 27678 was isolated from healthy human feces. Analysis of metagenomic datasets demonstrated that B. dentium is common in healthy pediatric and adult stool specimens, with a relative enrichment in children suggesting that microbe-derived GABA signaling may be developmentally important during childhood.
With our finding that microbial gadB is highly enriched in human stool, relative to other body sites, we explored the possibility that local GABAergic signals originating from the GI tract regulate gut-brain function. We have shown that the addition of the microbial gadB gene in vivo can significantly increase luminal GABA concentrations in the intestine. Since GABA is a well-characterized inhibitory neurotransmitter involved in central and visceral pain perception, we chose to examine the physiologic effects of B. dentium-associated GABA in a rat FR model of visceral sensitivity. 54, 55 Here, we provide the first experimental demonstration of a direct link between a GABA-producing F I G U R E 4 Neuromodulatory effects of GABA-producing Bifidobacterium dentium ATCC 27678 administration on colonic sensory neuron activity. Control (Sham) and fecal retention (FR) rats were gavaged daily with GABA-producing, gadB-positive B. dentium or gadB-negative B. breve strains (n=4 rats and 20-24 neurons per treatment group). Colon-specific DRG neurons were isolated and used for the measurements of cell excitability by patch clamp recordings. The following parameters are displayed: (A) Resting membrane potential (RMP), (B) rheobase, (C) action potential spikes at 2× rheobase, (D) action potential spikes at 3× rheobase, (E) cell diameter, (F) membrane capacitance, (G) input resistance, (H) action potential threshold, (I) action potential amplitude, (J) action potential overshoot, (K) action potential duration, (L) action potential latency. 
